What Is the Treatment for Hepatic Tuberculosis?
Clinical Scenario
This first-line protocol addresses the treatment of Hepatic tuberculosis (ICD-11 1B12.7.3 / ICD-10 A18.8), applying a structured multi-phase regimen as the initial management approach.
Treatment Approach
Management follows the WHO shorter MDR-TB regimen — a structured approach combining multiple antimycobacterial agents, organised across an initial phase and a subsequent continuation phase, with daily dosing maintained throughout both phases.
The complete agent list, full phase structure, and clinical decision points are detailed in the protocol — not shown here.
References
- Kanamycin (an injectable agent), moxifloxacin, prothionamide, clofazimine, isoniazid, pyrazinamide and ethambutol, given together in an initial phase of 4 months (with the option of extending to 6 months if the patient is still positive on a sputum smear at the end of month 4).
- Followed by an intensive phase of 5 months of treatment with four of the medicines (moxifloxacin, clofazimine, pyrazinamide, and ethambutol).
- Medicines are taken once per day, all days of the week.
- If the intensive phase is prolonged, the injectable agent is only given three times a week after the fourth month.
View source ↗